Study population
PCOS polycystic ovary syndrome, overweight or obese [Study flowchart
The clinical trial ran from July 11th 2017 to April 31st 2021. Seventy-five patients diagnosed with overweight or obese [Study flowchart. PCOS polycystic ovary syndrome, GLP-1RA glucagon-like peptide-1 receptor agonist, CPA cyproterone acetate, EE ethinylestradiol